Full membership with PCG includes access to the PCG registry (REG001-09) as well as ALL of the PCG trials/protocols listed here.
REG001-09
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
BRE007-12
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
BRE008-12 (Closed to enrollment)
Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation
BRE009-23 Phase III Randomized trial of Conventionally Fractioned vs. Hypofractioned COMprehensive Nodal Irradiation for Breast Cancer using Pencil Beam Scanning PROton Therapy (COMPRO)
PAN009-18
A Phase III Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
GU002-10
A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate
GU003-10
Phase III Study of Mildly Hypo-fractionated Image Guided Proton Beam Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
GU010-18
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
LUN005-12 (Closed to enrollment)
A Phase I/II Study of Hypo-fractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
A Registry membership with PCG includes access to the PCG registry (REG001-09) only.
REG001-09
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
BRE007-12
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
BRE008-12 (Closed to enrollment)
Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation
BRE009-23 Phase III Randomized trial of Conventionally Fractioned vs. Hypofractioned COMprehensive Nodal Irradiation for Breast Cancer using Pencil Beam Scanning PROton Therapy (COMPRO)
PAN009-18
A Phase III Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
GU002-10
A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate
GU003-10
Phase III Study of Mildly Hypo-fractionated Image Guided Proton Beam Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
GU010-18
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
LUN005-12 (Closed to enrollment)
A Phase I/II Study of Hypo-fractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
Beaumont Health
3601 W. 13 Mile Rd
Royal Oak, MI
9730 Summers Ridge Rd
San Diego, CA
92121
5352 Linton Boulevard
Delray Beach
FL 33484
40 Enterprise Parkway
Hampton, VA
23666
8081 Innovation Park Dr.
Fairfax, VA
22031
850 West Baltimore Street
Baltimore, MD
21201
200 First Street SW
Rochester, MN
55905
5777 East Mayo Boulevard
Phoenix, AZ
85054
8900 North Kendall Drive
Miami, FL
33176
225 East 126th Street
New York, NY
10035
4455 Weaver Parkway
Warrenville, IL
60555
103 Cedar Grove Lane
Somerset, New Jersey
08873
5901 W Memorial Road
Oklahoma City, OK
73142
1570 N 115th Street
Seattle, WA
98133
1720 2nd Ave South
Birmingham, AL
35294
2015 North Jefferson Street
Jacksonville, FL
32206
2600 Kings Highway
Shreveport, LA
71103
PROTON COLLABORATIVE GROUP
CORPORATE OFFICE
4320 Winfield Road, Suite 200
Warrenville, IL 60555
Copyright © 2024 · PROTON COLLABORATIVE GROUP · All Rights Reserved · Designed & Developed By Symboliq Media